BiVictriX Therapeutics plc (BVX) Ord GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
BiVictriX gets patent for its lead asset in Japan
15 November 2023 12:55
(Sharecast News) - BiVictriX Therapeutics has received a patent grant from the Japanese Patent Office (JPO) for its lead asset BVX001, it announced on Wednesday.
-
BiVictriX posts promising preclinical data on leukaemia candidate
12 October 2023 13:44
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class 'Bi-Cygni' antibody drug conjugate (ADC)...
-
BiVictriX appoints Adrian Howd as its new finance chief
3 October 2023 10:14
(Sharecast News) - Biotechnology developer BiVictriX Therapeutics announced the appointment of Dr Adrian Howd as its chief financial officer (CFO) and chief business officer (CBO) on Tuesday.
-
BiVictriX secures US patent for flagship therapeutic asset
23 August 2023 14:29
(Sharecast News) - Cancer treatment developer BiVictriX Therapeutics has secured a significant patent from the United States Patent and Trademark Office (USPTO), it announced on Wednesday, for its flagship...
-
Michael Kauffman promoted to BiVictriX board chair
6 January 2023 15:03
(Sharecast News) - Cancer therapy developer BiVictriX Therapeutics announced on Friday that Dr Michael Kauffman has been appointed as its non-executive chairman.
-
BiVictriX identifies development lead for potential cancer drug
7 December 2022 16:35
(Sharecast News) - Cancer therapy-focussed biotechnology company BiVictriX Therapeutics has identified a development lead for its 'BVX001' programme, it announced on Wednesday.
-
BiVictriX upbeat on recent pipeline progress
11 July 2022 14:15
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on its pipeline on Monday, reporting "significant progress" with its lead candidate, 'BVX001'.
-
BiVictriX adds two new drug development programmes
23 February 2022 15:39
(Sharecast News) - Biotechnology company BiVictriX Therapeutics announced the expansion of its therapeutic pipeline on Wednesday, with two additional programmes - 'BVX002' and 'BVX003' -...
-
BiVictriX files four new cancer therapy patents in UK
21 February 2022 13:16
(Sharecast News) - Cancer therapy-focussed biotechnology company BiVictriX Therapeutics has filed four new patent applications in the UK, it announced on Monday, related to several novel cancer-specific...
-
BiVictriX taps Glyn Baker as its new finance chief
6 January 2022 15:25
(Sharecast News) - Cancer therapy biotechnology company BiVictriX Therapeutics announced the appointment of Glyn Baker as its chief financial officer on Thursday, in a non-board role.
Company announcements Announcements
-
Grant of Options – PDMR/Director Dealings
28 March 2024 07:00
BiVictriX Therapeutics
-
Holding(s) in Company
4 January 2024 12:30
BiVictriX Therapeutics
-
Holding(s) in Company
4 January 2024 12:30
BiVictriX Therapeutics
-
BiVictriX Hosts Inaugural Roundtable Discussion
4 January 2024 07:00
BiVictriX Therapeutics
-
Board Change
5 December 2023 11:08
BiVictriX Therapeutics
-
Pipeline update on BVX002
30 November 2023 07:00
BiVictriX Therapeutics
-
Holding(s) in Company
22 November 2023 17:14
BiVictriX Therapeutics
-
Patent Granted in Japan
15 November 2023 07:00
BiVictriX Therapeutics
-
Extended Survival Rates Reported with BVX001
12 October 2023 07:00
BiVictriX Therapeutics
-
Appointment of Adrian Howd as CFO and CBO
3 October 2023 07:00
BiVictriX Therapeutics
-
Interim Results
19 September 2023 07:00
BiVictriX Therapeutics
-
Total Voting Rights
31 August 2023 07:00
BiVictriX Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.